Dopamine D2/3 receptor antagonism reduces activity-based anorexia

Dopamine receptor antagonism by the novel antianxiety drug, buspirone.

Buspirone is an anxiolytic drug with a clinical potency similar to that of diazepam, but it lacks affinity for diazepam of y-aminobutyric acid (GABA) binding sites. Because previous reports suggested that buspirone may possess dopamine (DA) agonist activity, buspirone was tested for effects on DA neurotransmission. At presynaptic DA receptors, unlike other DA agonists, buspirone inhibited neith...

Dopamine and anorexia nervosa.

We have suggested that reduced food intake increases the risk for anorexia nervosa by engaging mesolimbic dopamine neurons, thereby initially rewarding dieting. Recent fMRI studies have confirmed that dopamine neurons are activated in anorexia nervosa, but it is not clear whether this response is due to the disorder or to its resulting nutritional deficit. When the body senses the shortage of n...

Kava and dopamine antagonism.

Dopamine antagonism inhibits anorectic behavior in an animal model for anorexia nervosa.

Excessive physical activity is commonly described as symptom of Anorexia Nervosa (AN). Activity-based anorexia (ABA) is considered an animal model for AN. The ABA model mimics severe body weight loss and increased physical activity. Suppression of hyperactivity by olanzapine in anorectic patients as well as in ABA rats suggested a role of dopamine and/or serotonin in this trait. Here, we invest...

Leukotriene B4 receptor antagonism reduces monocytic foam cells in mice.

Leukotriene B4 (LTB4) is a potent chemotactic agent that activates monocytes through the LTB4 receptor (BLTR). We tested the hypothesis that LTB4 receptor blockade would slow atherosclerotic progression by inhibiting monocyte recruitment. Homozygous low-density receptor knockout (LDLr(-/-)) mice and apolipoprotein E deficient (apoE(-/-)) mice were treated with a specific LTB4 receptor antagonis...